PCN203 HEALTH-CARE RESOURCE USE AND COSTS IN AML-PATIENTS UNDERGOING STEM CELL TRANSPLANTATION

To estimate the cost of treatment-resource use and costs associated with sick leave (SL) and early retirement (ER) in patients below the age of 60 years with AML undergoing allogenic stem cell transplantation (SCT). This study was a national population-based retrospective database study performed on Swedish data. Patients diagnosed with AML between 2007 and 2015 were identified in the Swedish Cancer Registry, along with vital status. Data on resource use were collected from registers for inpatient- and outpatient specialized care and prescribed drugs. Data on SL and ER came from the Swedish Social Insurance Agency (absent days costed with the mean salary in Sweden). Hospital care resource use was costed using diagnosis-related group (DRG) remunerations, and includes cost of inpatient drugs. The occurrence of SCT was identified based on procedure codes as recorded in the NPR. Mean costs per patient were estimated per month and survival was analysed using Kaplan Meier survival estimations. Expected five-years costs were estimated by multiplying mean costs with survival estimates for each month, using the method described by Lin et al. to account for right censoring. Maximum follow-up was five years. A total of 361 patients under 60 years diagnosed with AML undergoing SCT were identified. Patients could undergo SCT at any stage during the disease (within the 5-year follow-up). The 5-year survival rate was 56.5%. The mean time from diagnosis to SCT was 228 days, the median time to SCT was 154. Expected 5-year cost per patient was estimated to €240,587. Of this, €142,080 were from costs of hospitalizations, €28,156 from outpatient visits, €11,823 from prescribed drugs, and €58,528 from SL/ER. Cost of AML in patients diagnosed below 60 years and undergoing SCT is high. Initially, costs are mainly driven by inpatient-care, while longer-term costs are substantially affected by SL/ER.